Lisa Rojkjaer, M.D. has been appointed vice president and head of clinical development at MorphoSys. Dr. Rojkjaer joins the company from Novartis Pharma, where she was most recently head of medical affairs, hematology, Europe, responsible for all clinical activities for Novartis’s hematology portfolio including Gleevec and Exjade. Prior to Novartis, she spent five years with Novo Nordisk in Copenhagen, Denmark and Princeton, NJ, as the director of global medical affairs biopharmaceuticals and later director, clinical development hematology.

“We are committed to building an excellent development organization by hiring top talent. Thus, I am particularly delighted to welcome Lisa Rojkjaer to occupy a key position in our growing development team,” commented Dr. Arndt Schottelius, chief development officer of MorphoSys. “Lisa brings extensive experience of drug development in the pharmaceutical industry, which will support us in our plans to advance and expand our proprietary pipeline and to develop a constant flow of valuable drug candidates.”

“I’m looking forward to working with the entire R&D team at MorphoSys to execute the company’s strategy and move antibody programs through clinical trials quickly and efficiently. Through both my academic and medical careers as well as my time within the pharmaceutical industry I gained profound scientific and drug development knowledge in hematology and oncology, which I will apply to advance MorphoSys’s growing clinical pipeline,” said Dr. Rojkjaer.

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference